Global Hemp Group Inc. (CSE GHG | OTC GBHPF | FRA GHG) Revenue and Competitors

North Vancouver, NC USA

Location

N/A

Total Funding

Medical

Industry

Employee Data

  • Global Hemp Group Inc. (CSE GHG | OTC GBHPF | FRA GHG) has 15 Employees.(i)
  • Global Hemp Group Inc. (CSE GHG | OTC GBHPF | FRA GHG) grew their employee count by 50% last year.

Global Hemp Group Inc. (CSE GHG | OTC GBHPF | FRA GHG)'s People

NameTitleEmail/Phone
1
Interim President & CEOReveal Email/Phone
2
DirectorReveal Email/Phone
3
Director, and Strategic advisorReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$7.5M21327%N/AN/A
#2
$7.5M10213%N/AN/A
#3
N/A10%N/AN/A
#4
N/A40%N/AN/A
#5
N/A7-12%N/AN/A
#6
N/A1633%N/AN/A
#7
N/A433%N/AN/A
#8
$15M130-11%N/AN/A
#9
N/A61-3%N/AN/A
#10
$15M287-4%N/AN/A
Add Company

What Is Global Hemp Group Inc. (CSE GHG | OTC GBHPF | FRA GHG)?

Global Hemp Group Inc. (CSE: GHG / OTC: GBHPF / FRANKFURT: GHG) is company currently focused on two business segments: the development and promotion of hemp-based products that are sustainable, environmentally friendly, and have a positive impact on society. To further support and innovate, GHG has established a R&D Division to actively pursue the development of Intellectual Property that can be patented for implementation at its projects and beyond. The Division is led by Prof. Víctor M. Castaño, Ph.D. whose career has focused in the areas of applied science and technology.\n\nGHG has expanded its scope of business into natural biologic therapeutics by acquiring the exclusive licensing of patents and IP from B-Organic R&D Corp. (Bioactive Lipid Agents (“BLA”) technology, a patented innovative matrix which is able to increase the solubility and bioavailability of numerous “poorly soluble pharma ingredients” including cannabinoids) and Apollon Formularies plc (a UK-based international pharmaceutical company developing cancer treatments from natural biologics, including cannabinoids, functional mushrooms, and combinations of these compounds, which to date have shown successful independent, third-party results in pre-clinical testing).

keywords:N/A

N/A

Total Funding

15

Number of Employees

N/A

Revenue (est)

50%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$1.3M157%N/A
#2
$1.5M17N/AN/A
#3
$0.6M18-22%$10.4M
#4
$1.7M19N/AN/A
#5
$2.3M23N/AN/A